ACADIA PHARMACEUTICALS INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Acadia reported Q3 2026 GAAP revenues of $342M (+23% YoY), with DAYBUE net sales of $140M (+39% YoY, driven by DAYBUE STIX uptake) and NUPLAZID net sales of $202M (+14% YoY). The company raised FY2026 DAYBUE guidance to $505–$520M (from $480–$510M) and narrowed total revenue guidance to $1.265–$1.295B. Net income was $54M ($0.31 diluted EPS) vs. $72M ($0.42 diluted EPS) in Q3 2025. Cash position improved to $976M. Regulatory wins: FDA Fast Track designation for remlifanserin in Lewy body dementia psychosis, EU approval and Germany launch of DAYBU, and U.S. patent extension through March 2041 for trofinetide. Phase 2 RADIANT data for remlifanserin in Alzheimer's disease psychosis supported Phase 3 advancement.
Why this rating
Strong revenue growth (+23%) and raised DAYBUE guidance are meaningful for a $2.3B company; regulatory wins support pipeline. Moderate event—solid quarterly execution but not transformational; EPS down YoY despite revenue growth due to SG&A expansion.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.